Current state and future perspective of cardiovascular medicines derived from natural products
Chunhui Zhao,Sen Li,Junhong Zhang,Yuanyun Huang,Luoqi Zhang,Feng Zhao,Xia Du,Jinli Hou,Tong Zhang,Chenjing Shi,Ping Wang,Ruili Huo,Owen L Woodman,Cheng Xue Qin,Haiyu Xu,Luqi Huang,Owen L. Woodman
DOI: https://doi.org/10.1016/j.pharmthera.2020.107698
2020-12-01
Abstract:<p>The contribution of natural products (NPs) to cardiovascular medicine has been extensively documented, and many have been used for centuries. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Over the past 40 years, approximately 50% of newly developed cardiovascular drugs were based on NPs, suggesting that NPs provide essential skeletal structures for the discovery of novel medicines. After a period of lower productivity since the 1990s, NPs have recently regained scientific and commercial attention, leveraging the wealth of knowledge provided by multi-omics, combinatorial biosynthesis, synthetic biology, integrative pharmacology, analytical and computational technologies. In addition, as a crucial part of complementary and alternative medicine, Traditional Chinese Medicine has increasingly drawn attention as an important source of NPs for cardiovascular drug discovery. Given their structural diversity and biological activity NPs are one of the most valuable sources of drugs and drug leads. In this review, we briefly described the characteristics and classification of NPs in CVDs. Then, we provide an up to date summary on the therapeutic potential and the underlying mechanisms of action of NPs in CVDs, and the current view and future prospect of developing safer and more effective cardiovascular drugs based on NPs.</p>
pharmacology & pharmacy